ADC Therapeutics

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ADC Therapeutics posts robust Q4 results, eyes pipeline expansion

ADC Therapeutics delivered strong financial results, bolstered by Zynlonta's sales growth and a healthy cash position.
Strategic decisions on pipeline programs and market access initiatives demonstrate a focus on long-term growth and profitability.
While facing challenges such as market access delays and community adoption hurdles, ADC Therapeutics remains poised for success with multiple growth opportunities ahead.

ADC Therapeutics accelerates pipeline progress and optimizes ZYNLONTA's potential

ADC Therapeutics is making strides in pipeline prioritization and operational efficiencies, focusing on ZYNLONTA's commercial success.
The company faces challenges in navigating market dynamics and implementing strategic changes while capitalizing on growth opportunities.
Opportunities lie in expanding trial sites, exploring potent combinations, and leveraging the new go-to-market model for enhanced performance.
Overall, ADC Therapeutics aims for sustained growth through strategic resource allocation and operational enhancements.

ADC Therapeutics reports revenue growth and strategic expansions in Q2

ADC Therapeutics showcased solid Q2 performance with revenue growth and strategic expansions.
While facing challenges in clinical trials and market dynamics, the company is leveraging strengths in portfolio investments and market positioning.
Opportunities lie in upcoming milestones, international expansions, and innovative sales strategies for sustained growth.

ADC Therapeutics reports mixed Q3 results, positive pipeline outlook

ADC Therapeutics faced challenges in ZYNLONTA sales but showcased positive pipeline updates and promising Cami trial results.
Management's focus on cost control and cash preservation aligns with maintaining financial stability until mid-2025.
Analysts' inquiries into commercial strategies and regulatory timelines reflect market interest and potential growth opportunities.
Overall, ADCT's performance highlights a mix of challenges, strengths, and opportunities in navigating the competitive landscape.

ADC Therapeutics reports robust earnings, eyes expansion in oncology market

ADC Therapeutics demonstrated strong financial performance and progress in clinical trials, positioning itself well for future growth. Strategic focus on key pipelines and real-world data strategies highlight a commitment to innovation.
While facing competition and evolving treatment landscapes, the company has opportunities to expand ZYNLONTA and leverage next-gen platforms. Ongoing partnership discussions and upcoming trial results offer avenues for advancement.
Challenges include market differentiation, safety data focus, and successful trial enrollment. Managing these hurdles while capitalizing on growth opportunities will be crucial for ADC Therapeutics' future success.

ADCT reports revenue growth and strategic advancements in Q1

ADCT's Q1 performance reflects revenue growth, cost management, and strategic investments in pipeline development and financial stability.
Strengths lie in ZYNLONTA's performance, successful fundraising, disciplined capital allocation, and diversified pipeline progress.
Challenges include market competition, net losses, regulatory considerations, and balancing expenses with revenue growth.
Opportunities arise from expanding into new indications, advancing therapeutic candidates, regulatory engagements, and solid tumor pipeline growth.

ADC Therapeutics achieves profitability driven by ZYNLONTA in hematology

ADC Therapeutics demonstrated strong financial performance with commercial profitability and cost management improvements.
The company's focus on hematology and advancements in product pipeline position them for future growth.
While facing challenges in sales variability and market competition, ADC Therapeutics has opportunities for expansion and differentiation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ADC Therapeutics (ADCT) is trading well below its cash on hand, underlying its severely poor sentiment from investors. ADCT's main molecule, loncastuximab tesirine, has shown positive results in the relapse/refractory setting. ADCT has other pipeline projects in development, with data from phase 1 studies expected in the first half of 2024.

ADC Therapeutics: Navigating A Swirling Drain

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

ADC Therapeutics SA (NYSE:ADCT ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Eugenia Litz - Vice President of Investor Relations and Corporate Communications Ameet Mallik - Chief Executive Officer Kristen Herrington-Smith - Chief Commercial Officer Mohamed Zaki - Chief Medical Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Naureen Quibria - Capital One Securities Brian Cheng - JPMorgan Operator Welcome to the ADC Therapeutics Third Quarter 2023 Financial Results Conference Call. My name is Cathy and I will be your operator for today's call.

ADC Therapeutics SA (ADCT) Q3 2023 Earnings Call Transcript

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that on October 10, 2023, it received a notice from the New York Stock Exchange (NYSE) that the Company is not in compliance with the continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual, which requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period.

ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards

3Q 2023 ZYNLONTA® 1 net sales of $14.3 million reflect disruption following restructuring of commercial organization, increased competition and higher gross-to-net deductions

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14th at 10:00 a.m. GMT.

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination

ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30 a.m. ET to report financial results for the third quarter 2023 and provide business updates.

ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023

LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi, Ph.D., as Chief Scientific Officer (CSO).

Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in September.

ADC Therapeutics to Participate in September Investor Conferences

LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals

ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)

ADC Therapeutics is a small-cap biotech with an approved antibody-drug conjugate in lymphoma. The company has faced setbacks but has cash on hand and promising clinical data outside of their flagship product. They are trading below their enterprise value, making them a potentially strong opportunity for risk-tolerant investors.

ADC Therapeutics: Slowly Moving Toward Solvency

2Q 2023 ZYNLONTA® 1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. EDT to report financial results for the second quarter 2023 and provide business updates.

ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

NEW YORK , July 25, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for ZYNLONTA® (loncastuximab tesirine-lpyl), which is seeking an indication for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy in China. The BLA has been granted priority review by the NMPA.

Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics SA (ADCT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

ADC Therapeutics SA (ADCT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -34.06% in 4 Weeks, Here's Why the Trend Might Reverse for ADC Therapeutics SA (ADCT)

ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.

ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study

ADC Therapeutics said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for treating a type of blood cancer over safety concerns.

ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy

LAUSANNE, Switzerland, July 11, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial (ClinicalTrials.gov Identifier: NCT05144009) evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

Strengthens the Board with the election of Robert W. Azelby as director Board will be comprised of nine directors; gratitude expressed for contributions of outgoing directors LAUSANNE, Switzerland, June 15, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced the election of Robert W.

ADC Therapeutics Announces Evolution of Board of Directors

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

LAUSANNE, Switzerland, June 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 8th at 8:30 a.m. EDT.

News for ADC Therapeutics Stock (ADCT)